Mink therapeutics to present data from inkt cell programs at sitc 2024

New york, oct. 04, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the society for immunotherapy of cancer's (sitc) 29th annual meeting on november 6-10, 2024, in houston, texas. the presentations will showcase new preclinical data from mink's inkt cell programs, agent-797 and prame-tcr.
INKT Ratings Summary
INKT Quant Ranking